This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Hill-Rom's Innovations Make Surgeries More Safe, Accurate
by Zacks Equity Research
Hill-Rom Holdings, Inc. (HRC) recently demonstrated the impact of surgical patient positioning on skin and nerve pressure-related injuries.
Becton (BDX) Gets FDA 510(k) for New Flow Cytometer System
by Zacks Equity Research
Becton, Dickinson and Company (BDX), popularly known as BD, recently announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
Fresenius (FMS) Acquires 70% Stake in Kunming Wuhua Hospital
by Zacks Equity Research
Fresenius Medical Care AG & Co. KGAA announced the acquisition of 70% equity interest in Kunming Wuhua Health Hospital in China.
PetMed Faces Concerns over New Order Sales, Competition
by Zacks Equity Research
On Apr 6, we issued an updated research report on Pompano Beach, FL-based PetMed Express, Inc. (PETS).
athenahealth Now a Strong Buy: Should You Add the Stock?
by Zacks Equity Research
On Apr 5, athenahealth (ATHN) was raised to a Zacks Rank #1 (Strong Buy).
Medtronic (MDT) Less-Invasive HVAD Pump Results Positive
by Zacks Equity Research
Medtronic plc (MDT), a leading name in medical device space, recently presented preliminary results from its HVAD LATERAL study.
Medidata & TESARO Win CARE 'Clinical Partnership' Award
by Zacks Equity Research
Medidata Solutions Inc. (MDSO) recently announced the receipt of the 'Clinical Partnership of the Year' award at the second annual Clinical and Research Excellence (CARE) Awards, courtesy of its 'unique technology collaboration' with TESARO.
Omnicell's Aesynt Buyout Looks Promising amid Several Woes
by Zacks Equity Research
On Apr 6, we issued an updated research report on Mountain View, CA-based Omnicell Inc. (OMCL).
Mazor Expects Higher Q1 Revenue, Receives Mazor X Orders
by Zacks Equity Research
Mazor Robotics Ltd. (MZOR), recently announced that it expects to report record first-quarter 2017 revenue of approximately $11.5 million compared with only $6.4 million in the year-ago quarter.
Medtronic HVAD System Results Positive for Long-Term Therapy
by Zacks Equity Research
Medical device major Medtronic plc (MDT) recently released results of its ENDURANCE Supplemental trial in regard to HVAD System.
IDEXX Laboratories' CAG Revenues Solid, Competition Rife
by Zacks Equity Research
On Apr 5, we issued an updated research report on Delaware NJ-based IDEXX Laboratories, Inc. (IDXX).
Walgreens Boots (WBA) Meets Q2 Earnings, Retains EPS View
by Zacks Equity Research
Walgreens Boots Alliance, Inc. (WBA) reported adjusted earnings per share (EPS) of $1.36 in second-quarter fiscal 2017, up 6.1% year over year.
Should You Retain Acadia Healthcare Stock in Your Portfolio?
by Zacks Equity Research
The Acadia Healthcare Company, Inc. (ACHC) stock gained momentum in the first quarter of 2017
Teleflex (TFX) Acquires Medical Device Provider Pyng Medical
by Zacks Equity Research
Teleflex Inc. (TFX), a global provider of medical technologies, announced that it has acquired Pyng Medical Corporation.
Becton, Dickinson Takes Over Caesarea Medical Electronics
by Zacks Equity Research
Becton, Dickinson and Company (BDX), popularly known as BD, recently announced that it has acquired Caesarea Medical Electronics.
WellCare and Catholic Health Team Up to Improve Health Care
by Zacks Equity Research
WellCare of New York, Inc., a wholly owned subsidiary of WellCare Health Plans, Inc. (WCG), recently inked a deal with Catholic Health and Catholic Medical Partners to enhance its health care services.
Walgreens, Prime Form Central Specialty & Mail Service Company
by Zacks Equity Research
Walgreens Boots Alliance (WBA), in a partnership with pharmacy benefit manager (PBM) Prime Therapeutics LLC, recently formed a combined central specialty pharmacy and mail services company AllianceRx .
Varian (VAR) Eclipse Software Tops in International Studies
by Zacks Equity Research
Varian Medical Systems, Inc. (VAR) recently announced that its Eclipse treatment planning software has topped in two competitive international plan studies.
NuVasive Receives FDA 510(k) Clearance in Cervical Spine
by Zacks Equity Research
NuVasive Inc. (NUVA) received the U.S. FDA's 510(K) clearance for one of its spine products.
Amedisys to Buy East Tennessee to Expand in Personal Care
by Zacks Equity Research
Amedisys Inc. (AMED) recently signed a definitive agreement to buy substantially all of the assets of a Knoxville, TN-based personal care provider, East Tennessee Personal Care Service.
Boston Scientific (BSX) Inks Agreement to Acquire Symetis SA
by Zacks Equity Research
Boston Scientific Corporation (BSX) recently signed a definitive agreement to acquire Switzerland-based Symetis SA for $435 million in up-front cash, in a bid to fortify its structural heart business in Europe.
PAREXEL (PRXL) Launches Sensor for Clinical Trial Market
by Zacks Equity Research
PAREXEL International Corporation (PRXL), a global biopharmaceutical services company and provider of clinical research and logistics, recently announced the launch of its patient sensor solution.
AngioDynamics (ANGO) Beats on Q3 Earnings, Raises 2017 View
by Zacks Equity Research
AngioDynamics Inc. (ANGO), a leading provider of minimally invasive medical devices, reported adjusted earnings of 19 cents per share in the third quarter of fiscal 2017.
Abbott's St Jude Buyout to Boost Business, Risks Remain
by Zacks Equity Research
On Mar 31, we updated our research report on medical device major, Abbott Laboratories (ABT).
Community Health Completes Tender Offer for Senior Notes
by Zacks Equity Research
Community Health Systems, Inc. (CYH) recently announced the completion of the previously announced cash tender offer for its outstanding 5.125% Senior Secured Notes, due 2018.